Moderna developing single-shot vaccine booster for COVID, flu
Advertisement
New Delhi: Moderna Inc said on Thursday it is developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot.
The company hopes to eventually add vaccines it is working on for respiratory syncytial virus and other respiratory diseases as an annual shot.
"We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster," Moderna Chief Executive Officer Stephane Bancel said during a presentation to update investors on its drugs in development.
"We believe Moderna could be first to market in this important new opportunity," he said.
Moderna and Pfizer Inc and German vaccine partner for BioNTech SE are already expected to reap billions of dollars from COVID-19 booster shots, analysts and healthcare investors said. Adding influenza and other diseases could further boost those profits.
Moderna shares were up 6% on Thursday.
The drugmaker already had several influenza vaccine candidates in development. The new vaccine combines the experimental flu shot that is furthest along with its COVID-19 vaccine.
The company has also already started clinical trials for an RSV vaccine in older adults.
Novavax Inc said on Wednesday it has initiated an early-stage study to test its combined flu and COVID-19 vaccine.
Moderna also provided updates on its ongoing mid-stage trial testing its authorized COVID-19 vaccine in children aged 6 months to 11 years old. It is testing a 50-microgram dose of the shot in the pediatric trial involving 4,000 children.
Moderna's vaccine, which received an emergency use authorization for two 100-microgram doses for people aged 18 and older in the United States in December, is currently under an FDA review for use in adolescents.
Moderna said dose selection studies for different age groups such as 2 years to less than 6 years, and 6 months to below 2 years old, were still underway.
The Pfizer/BioNTech vaccine was authorized for those aged 12 to 15 earlier this year.
Read also: Covid-19: Moderna seeks USFDA nod for booster shot
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.